Latest & greatest articles for rivaroxaban

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rivaroxaban or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on rivaroxaban and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for rivaroxaban

61. Apixaban and Rivaroxaban for Stroke Prevention in Atrial Fibrillation

Apixaban and Rivaroxaban for Stroke Prevention in Atrial Fibrillation Title: Apixaban and Rivaroxaban for Stroke Prevention in Atrial Fibrillation: Safety DATE: 28 March 2014 RESEARCH QUESTIONS 1. What are the adverse events associated with the use of apixaban? 2. What are the adverse events associated with the use of rivaroxaban? KEY MESSAGE Twenty-two systematic reviews/meta-analyses, 24 randomized controlled trials, and three non- randomized studies were identified regarding adverse events (...) associated with the use of apixaban and rivaroxaban. METHODS A limited literature search was conducted on key resources including PubMed, The Cochrane Library (2014, Issue 3), University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. Methodological filters were applied to limit retrieval to safety data. Where possible, retrieval was limited to the human population. The search was also limited

2014 Canadian Agency for Drugs and Technologies in Health - Rapid Review

62. Rivaroxaban - Thromboembolic events (venous), pulmonary embolism

Rivaroxaban - Thromboembolic events (venous), pulmonary embolism Common Drug Review CDEC Meetings: October 16, 2013; January 15, 2013; March 19, 2014 Notice of Final Recommendation — March 26, 2014 Page 1 of 6 © 2014 CADTH CDEC FINAL RECOMMENDATION RIVAROXABAN (Xarelto — Bayer Inc.) New Indication: Pulmonary Embolism Recommendation: CDEC recommends that rivaroxaban be listed for the treatment of VTE (DVT and PE) and prevention of recurrent DVT and PE, for a duration of up to six months (...) . If treatment is to be extended beyond six months, the following condition must be met: Condition: ? A reduction in price is required if rivaroxaban is funded for a treatment duration of more than six months. Reason for the Recommendation: 1. In one randomized controlled trial (RCT) involving patients with acute PE (EINSTEIN-PE), rivaroxaban was reported to be non-inferior to a regimen of enoxaparin plus a vitamin K antagonist (VKA) based on the incidence of recurrent DVT, non-fatal PE, or fatal PE. Given

2014 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

63. The safety of new oral anticoagulants dabigatran, rivaroxaban, apixaban and edoxaban in conditions that elevate drug concentrations

The safety of new oral anticoagulants dabigatran, rivaroxaban, apixaban and edoxaban in conditions that elevate drug concentrations Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2014 PROSPERO

64. Rivaroxaban - stroke prevention in patients with atrial fibrillation

Rivaroxaban - stroke prevention in patients with atrial fibrillation Common Drug Review CDEC Meeting – June 19, 2013 Notice of CDEC Final Recommendation – July 18, 2013 Page 1 of 6 © 2013 CADTH CDEC FINAL RECOMMENDATION RIVAROXABAN (Xarelto – Bayer Inc.) Indication: Stroke Prevention in Atrial Fibrillation Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that rivaroxaban be listed for the prevention of stroke and systemic embolism in patients with atrial fibrillation who (...) meet all of the following clinical criteria: Clinical Criteria: 1. Patients with a CHADS 2 score = 2. 2. Patients who are unable to readily achieve adequate anticoagulation with warfarin. Reasons for the Recommendation: 1. In one large, double-blind, randomized controlled trial (RCT) of patients with a CHADS 2 score of greater than or equal to 2 (ROCKET-AF), rivaroxaban was reported to be non- inferior, but not superior, to adjusted-dose warfarin, based on the incidence of stroke or systemic

2013 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

65. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation Full Text available with Trip Pro

Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation Harrington AR, Armstrong EP, Nolan PE, Malone DC Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) . Interventions The four interventions were warfarin, apixaban 5mg twice daily, dabigatran 150mg twice daily, and rivaroxaban 20mg once daily. Warfarin dose was assumed to be adjusted to achieve the patient's target international normalised ratio (INR). Location/setting USA/in-patient and out-patient care. Methods Analytical approach: A Markov model, with one-month cycles, combined the published data. The time horizon was 30 years and the authors stated that the perspective was societal. Effectiveness data

2013 NHS Economic Evaluation Database.

66. Clinical outcomes with rivaroxaban in patients transitioned from vitamin k antagonist therapy: a subgroup analysis of a randomized trial. (Abstract)

Clinical outcomes with rivaroxaban in patients transitioned from vitamin k antagonist therapy: a subgroup analysis of a randomized trial. In ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation), a large randomized, clinical trial, rivaroxaban was noninferior to warfarin in preventing stroke or systemic embolism in patients with atrial fibrillation.To determine the efficacy (...) and safety of rivaroxaban compared with warfarin among vitamin K antagonist (VKA)-naive and VKA-experienced patients.Prespecified subgroup analysis. (ClinicalTrials.gov: NCT00403767).Global.14,264 persons with atrial fibrillation.Interaction of the relative treatment effect of rivaroxaban and warfarin on stroke or systemic embolism among VKA-naive and VKA-experienced patients.Overall, 7897 (55.4%) patients were VKA-experienced and 6367 (44.6%) were VKA-naive. The effect of rivaroxaban versus warfarin

2013 Annals of Internal Medicine Controlled trial quality: predicted high

67. Meta-Analysis of Rivaroxaban and Bleeding Risk (Abstract)

Meta-Analysis of Rivaroxaban and Bleeding Risk Rivaroxaban, a factor Xa inhibitor, is a new oral anticoagulant that has been developed as an alternative to vitamin K antagonists. However, its safety remains unclear. Reported randomized controlled trials comparing the safety of rivaroxaban with that of vitamin K antagonists (warfarin, acenocoumarol, phenprocoumon, and fluindione) were systematically searched. Inclusion was restricted to studies of ≥30 days' treatment duration. Safety end points (...) examined included major and clinically relevant nonmajor bleeding, as well as mortality. Data were pooled across randomized controlled trials using random-effects meta-analysis models. Five randomized controlled trials including 23,063 patients that met the inclusion criteria were identified. Patients received treatment for nonvalvular atrial fibrillation (n = 14,264), deep vein thrombosis (n = 3,967), or acute symptomatic pulmonary embolism (n = 4,832). Overall, rivaroxaban was not associated

2013 EvidenceUpdates

68. Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287)

Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287) Overview | Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism | Guidance | NICE Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism Technology appraisal guidance [TA287] Published date: 26 June 2013 Share Save Guidance on rivaroxaban (Xarelto) for treating pulmonary embolism and for preventing a further deep vein

2013 National Institute for Health and Clinical Excellence - Technology Appraisals

69. Randomised controlled trial: Oral treatment of acute pulmonary embolism with a fixed dose of rivaroxaban is non-inferior to standard treatment

Randomised controlled trial: Oral treatment of acute pulmonary embolism with a fixed dose of rivaroxaban is non-inferior to standard treatment Oral treatment of acute pulmonary embolism with a fixed dose of rivaroxaban is non-inferior to standard treatment | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our (...) . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Oral treatment of acute pulmonary embolism with a fixed dose of rivaroxaban is non-inferior to standard treatment Article Text

2013 Evidence-Based Medicine

70. New oral anticoagulants apixaban (Eliquis?), dabigatran (Pradaxa) and rivaroxaban (Xarelto?)

New oral anticoagulants apixaban (Eliquis?), dabigatran (Pradaxa) and rivaroxaban (Xarelto?) New oral anticoagulants apixaban (Eliquis▼), dabigatran (Pradaxa) and rivaroxaban (Xarelto▼) - GOV.UK GOV.UK uses cookies to make the site simpler. or Search New oral anticoagulants apixaban (Eliquis▼), dabigatran (Pradaxa) and rivaroxaban (Xarelto▼) Risk of serious haemorrhage—clarified contraindications apply to all 3 medicines. Published 11 December 2014 From: Therapeutic area: Contents Article (...) , direct inhibitor of free thrombin, fibrin-bound thrombin and thrombin-induced platelet aggregation. Apixaban (Eliquis ▼) and rivaroxaban (Xarelto ▼) are direct, highly selective, orally active inhibitors of activated factor X (factor Xa). All 3 new oral anticoagulants are licensed for: prevention of venous thromboembolic events in adults who have had elective total hip-replacement or knee-replacement surgery prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation

2013 MHRA Drug Safety Update

71. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. Full Text available with Trip Pro

Rivaroxaban for thromboprophylaxis in acutely ill medical patients. The clinically appropriate duration of thromboprophylaxis in hospitalized patients with acute medical illnesses is unknown. In this multicenter, randomized, double-blind trial, we evaluated the efficacy and safety of oral rivaroxaban administered for an extended period, as compared with subcutaneous enoxaparin administered for a standard period, followed by placebo.We randomly assigned patients 40 years of age or older who were (...) hospitalized for an acute medical illness to receive subcutaneous enoxaparin, 40 mg once daily, for 10±4 days and oral placebo for 35±4 days or to receive subcutaneous placebo for 10±4 days and oral rivaroxaban, 10 mg once daily, for 35±4 days. The primary efficacy outcomes were the composite of asymptomatic proximal or symptomatic venous thromboembolism up to day 10 (noninferiority test) and up to day 35 (superiority test). The principal safety outcome was the composite of major or clinically relevant

2013 NEJM Controlled trial quality: predicted high

72. Dabigatran or rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety. Full Text available with Trip Pro

Dabigatran or rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety. 22977402 2012 09 18 2018 11 13 1481-4501 1 2 2010 CADTH technology overviews CADTH Technol Overv Dabigatran or rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety. e0111 Canadian Agency for Drugs and Technologies

2012 CADTH technology overviews

73. Rivaroxaban - Deep-Vein Thrombosis (treatment), without Symptomatic Pulmonary Embolism

Rivaroxaban - Deep-Vein Thrombosis (treatment), without Symptomatic Pulmonary Embolism Common Drug Review CDEC Meeting – July 18, 2012 Notice of CDEC Final Recommendation – August 16, 2012 Page 1 of 5 © 2012 CADTH CDEC FINAL RECOMMENDATION RIVAROXABAN (Xarelto – Bayer Inc.) New Indication: Deep Vein Thrombosis (Treatment) without Symptomatic Pulmonary Embolism Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that rivaroxaban be listed for the treatment of deep vein (...) thrombosis (DVT) in patients without symptomatic pulmonary embolism (PE), for a duration not to exceed six months. Reasons for the Recommendation: 1. In one large randomized controlled trial (RCT) of patients with acute symptomatic DVT without symptomatic PE (the EINSTEIN DVT trial), rivaroxaban was reported to be non- inferior to a regimen of enoxaparin plus a vitamin K antagonist (VKA) based on the incidence of recurrent DVT or PE. The majority of patients received treatment for six months or less

2012 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

74. Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a US payer's perspective

Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a US payer's perspective Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a US payer's perspective Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a US payer's perspective Duran A, Sengupta N, Diamantopoulos A, Forster F, Kwong L, Lees M Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study examined the cost-effectiveness of rivaroxaban versus enoxaparin for prevention of venous thromboembolism in patients who underwent major orthopaedic surgery such as total hip or total knee replacement

2012 NHS Economic Evaluation Database.

75. Rivaroxaban and usual care had similar rates of recurrent VTE and bleeding in symptomatic PE. (Abstract)

Rivaroxaban and usual care had similar rates of recurrent VTE and bleeding in symptomatic PE. 22910960 2012 10 19 2012 08 22 1539-3704 157 4 2012 Aug 21 Annals of internal medicine Ann. Intern. Med. ACP Journal Club: rivaroxaban and usual care had similar rates of recurrent VTE and bleeding in symptomatic PE. JC2-6 10.7326/0003-4819-157-4-201208210-02006 Witt Daniel M DM Kaiser Permanente Colorado, Aurora, Colorado, USA. eng Comment Journal Article United States Ann Intern Med 0372351 0003-4819

2012 Annals of Internal Medicine

76. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons Full Text available with Trip Pro

Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic (...) for the use of new oral anticoagulants for prophylaxis against venous thromboembolism after total hip or knee replacement. Searching MEDLINE and Cochrane Central Register of Controlled Trials (CENTRAL) were searched up to April 2011. Clinical trial registries, relevant conference proceedings and websites of regulatory agencies were searched. The search strategy was available online. There were no language restrictions. Study selection Randomised controlled trials (RCTs) that compared rivaroxaban (10mg

2012 DARE.

77. Rivaroxaban - Atrial fibrillation, stroke prevention

Rivaroxaban - Atrial fibrillation, stroke prevention Common Drug Review CDEC Meeting – March 21, 2012 Notice of CDEC Final Recommendation – April 19, 2012 Page 1 of 6 © 2012 CADTH CDEC FINAL RECOMMENDATION RIVAROXABAN (Xarelto – Bayer Inc.) New Indication: Atrial Fibrillation, Stroke Prevention Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that rivaroxaban be listed for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (...) , in whom warfarin is indicated, and who meet all of the following criteria: • Are unable to achieve adequate anticoagulation with warfarin, and • Have a CHADS 2 score of = 2. Reasons for the Recommendation: 1. In one large double-blind randomized controlled trial (RCT) of patients with a CHADS 2 score of = 2 (ROCKET-AF), rivaroxaban was reported to be non-inferior, but not superior, to adjusted-dose warfarin, based on the incidence of stroke or systemic embolism. 2. At recommended doses of rivaroxaban

2012 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

78. Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden

Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 NHS Economic Evaluation Database.

79. ROCKET?AF: Rivaroxaban vs Warfarin in patients with Atrial Fibrillation

ROCKET?AF: Rivaroxaban vs Warfarin in patients with Atrial Fibrillation RXFILES TRIAL SUMMARY ORIGINALLY PREPARED BY: M JIN, REVISED BY: L KOSAR – UPDATED DECEMBER 2012 – WWW.RXFILES.CA Page 1 of 4 ROCKET-AF: Rivaroxaban vs Warfarin in patients with Atrial Fibrillation 1 Rivaroxaban Once daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in AF BOTTOM LINE In atrial fibrillation (AF) patients with an ? risk of stroke (mean CHADS (...) 2 score 3.5), rivaroxaban 20mg po daily: ? Was non-inferior (i.e. no worse than) to warfarin for ? stroke or systemic embolism ? Had less hemorrhagic strokes, systemic embolism & bleeding (critical, fatal & intracranial) versus warfarin ? Had more drops in hemoglobin =20 g/L, tranfusions, gastrointestinal bleeding, epistaxis & hematuria versus warfarin ? At time of publication, rivaroxaban for AF is approximately $100/month; 15mg, 20mg tablets. ? A Fib, ? Warfarin + monitoring ~$35/month

2012 RxFiles

80. Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256)

Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256) Overview | Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation | Guidance | NICE Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation Technology appraisal guidance [TA256] Published date: 23 May 2012 Share Guidance on rivaroxaban (Xarelto) for preventing stroke and systemic embolism in adults with non

2012 National Institute for Health and Clinical Excellence - Technology Appraisals